Is Oxyntomodulin legal in the United Kingdom?

Glucagon with eight extra amino acids on the end, which turns it into a weak dual agonist at both glucagon and GLP-1 receptors. The natural template for every GLP-1 and glucagon dual agonist.

Oxyntomodulin is the glucagon sequence plus an eight-residue tail, KRNRNNIA. That single structural fact explains its entire pharmacology and is why it belongs on this site.

Mechanism: A weak dual agonist at the glucagon receptor and the GLP-1 receptor, with no dedicated receptor. The proposed appeal of that combination is that GLP-1 receptor agonism suppresses appetite while glucagon receptor agonism raises energy expenditure, so the pair might reduce intake and increase output at once.

Regulatory history: Not approved and not marketed anywhere. Its therapeutic relevance is as a design template.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Oxyntomodulin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.